Shrikrupa Sales

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is the brand name for the injectable drug Tirzepatide, which represents a significant advance in the treatment of type 2 diabetes and is also used for chronic weight management. It is unique because it acts as a dual agonist, meaning it mimics the action of two naturally occurring incretin hormones in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action allows Mounjaro to improve blood sugar control by enhancing the body’s insulin secretion in a glucose-dependent manner, reducing the amount of sugar released by the liver, and slowing down gastric emptying. The delay in gastric emptying, along with the drug's effect on appetite centers in the brain, also leads to a significant reduction in appetite and increased satiety, which results in substantial weight loss. The medication is administered once weekly as a subcutaneous injection, and common side effects, especially upon initiation or dose escalation, are typically gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. Due to a serious but rare risk of thyroid C-cell tumors found in animal studies, Mounjaro carries a Boxed Warning and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Rybelsus 3mg is an oral tablet formulation of semaglutide, a medication primarily used for the management of type 2 diabetes. It is a once-daily prescription medicine that works as a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the action of a natural hormone in the body. Rybelsus is used in conjunction with a healthy diet and exercise to help adults with type 2 diabetes improve their blood sugar (glucose) control.